English
Insider transactions
EDGARJUPITER NEUROSCIENCES, INC.
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.
A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.
Window: transactions dated on or after 2025-11-20.
- Open-market purchases (code P)
- 0 transactions, — shares
- Open-market sales (code S)
- 0 transactions, — shares
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
Showing 1–13 of 13
| Date | Reporting owner | Code | Acquired or disposed | Shares | Price per share, as filed | Value (derived) | Shares owned after | Direct or indirect | Rule 10b5-1 box | Notes | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-31 Filed 2026-08-05 | Cutler Andrew Jon Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 472,222 | 0 | — | 472,222 | Direct (D) | No | F1
| Open filing 0001493152-26-036161 Read from the filing’s XML Dispute this row |
| 2026-06-29 Filed 2026-07-01 | Philipson Tomas Jan Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 536,428 | 0 | — | 536,428 | Direct (D) | No | F1
| Open filing 0001493152-26-031539 Read from the filing’s XML Dispute this row |
| 2026-06-02 Filed 2026-06-05 | Brady Allison W Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 100,000 | 0 | — | 100,000 | Direct (D) | No | F1
| Open filing 0001493152-26-027421 Read from the filing’s XML Dispute this row |
| 2026-06-02 Filed 2026-06-04 | Hemmerly Nicholas H. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 100,000 | 0 | — | 100,000 | Direct (D) | No | F1
| Open filing 0001493152-26-027364 Read from the filing’s XML Dispute this row |
| 2026-06-02 Filed 2026-06-04 | Weis Holger Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 100,000 | 0 | — | 100,000 | Direct (D) | No | F1
| Open filing 0001493152-26-027354 Read from the filing’s XML Dispute this row |
| 2026-06-02 Filed 2026-06-04 | ROSEN CHRISTER Director · Officer: CEO and Chairman | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 747,783 | 0 | — | 747,783 | Direct (D) | No | F1
| Open filing 0001493152-26-027365 Read from the filing’s XML Dispute this row |
| 2026-06-02 Filed 2026-06-04 | Elmasri Saleem Officer: Chief Financial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 525,565 | 0 | — | 525,565 | Direct (D) | No | F1
| Open filing 0001493152-26-027366 Read from the filing’s XML Dispute this row |
| 2026-06-02 Filed 2026-06-04 | Silva Alison D. Director · Officer: President and COO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 1,027,304 | 0 | — | 1,027,304 | Direct (D) | No | F1
| Open filing 0001493152-26-027362 Read from the filing’s XML Dispute this row |
| 2026-06-02 Filed 2026-06-04 | Kampf Julie B. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 100,000 | 0 | — | 100,000 | Direct (D) | No | F1
| Open filing 0001493152-26-027363 Read from the filing’s XML Dispute this row |
| 2026-06-02 Filed 2026-06-04 | Rosen Alexander Gustaf Erik Officer: Chief Administrative Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 341,843 | 0 | — | 341,843 | Direct (D) | No | F1
| Open filing 0001493152-26-027353 Read from the filing’s XML Dispute this row |
| 2026-06-02 Filed 2026-06-04 | Hayward Marshall A. Director · Officer: Chief Scientific Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 259,231 | 0 | — | 259,231 | Direct (D) | No | F1
| Open filing 0001493152-26-027361 Read from the filing’s XML Dispute this row |
| 2026-03-02 Filed 2026-07-13 | Hayward Marshall A. Director · Officer: Chief Scientific Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 225,000 | — | — | 2,995,077 | Direct (D) | No | F3
| Open filing 0001493152-26-033015 Read from the filing’s XML Dispute this row |
| 2026-03-02 Filed 2026-07-13 | Hayward Marshall A. Director · Officer: Chief Scientific Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 225,000 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 0 | Direct (D) | No | F3
| Open filing 0001493152-26-033015 Read from the filing’s XML Dispute this row |
Institutional holders (Form 13F)
Quarter ending 2026-09-30: 8,925 filings read, the latest filed 2026-11-19. Prior quarter ending 2026-06-30: 9,176 filings read.
Showing 1–9 of 9
| Manager | Shares or principal | Value as filed | Change from the prior quarter | Source |
|---|---|---|---|---|
| STATE STREET CORP Partly reported under another manager | 14,500 SH | 35,380 dollars | Not in the prior quarter’s filings read | Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row |
| VESTOR CAPITAL, LLC | 14,009 SH | 3,985 dollars | Higher by 11,816 Prior quarter: 2,193 | Open filing 0001132699-26-000007 Filed 2026-11-04 Dispute this row |
| JANE STREET GROUP, LLC Partly reported under another manager | 13,792 SH | 33,652 dollars | Lower by 519,603 Prior quarter: 533,395 | Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row |
| UBS Group AG Partly reported under another manager | 11,703 SH | 28,555 dollars | Not in the prior quarter’s filings read | Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,706 SH | 4,163 dollars | Lower by 126,336 Prior quarter: 128,042 | Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row |
| VANGUARD FIDUCIARY TRUST CO | 961 SH | 2,345 dollars | Lower by 83,212 Prior quarter: 84,173 | Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row |
| Nuveen, LLC Partly reported under another manager | 457 SH | 1,179 dollars | Not in the prior quarter’s filings read | Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row |
| MidFirst Bank | 13 SH | 32 dollars | Lower by 987 Prior quarter: 1,000 | Open filing 0002077076-26-000006 Filed 2026-11-16 Dispute this row |
| JPMORGAN CHASE CO Partly reported under another manager | 1 SH | 3 dollars | Not in the prior quarter’s filings read | Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row |
Managers in the prior quarter with no filing read for the latest
They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.
- Virtu Financial LLC 231,240 SH
- GEODE CAPITAL MANAGEMENT, LLC 156,127 SH
- XTX Topco Ltd 32,770 SH
- Tower Research Capital LLC (TRC) 28,786 SH
- NORTHERN TRUST CORP 25,346 SH
- StoneX Group Inc. 20,602 SH
- LEVEL FOUR ADVISORY SERVICES, LLC 10,000 SH
- CITIGROUP INC 546 SH
- Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
- Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
- A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
- A change is the difference between two quarter-end snapshots, not a trade.
- A position reported under another manager may also appear in that manager’s filing; rows are not added together.
- Holdings the securities list cannot place with this company, or places ambiguously, are not shown.
Trades by members of Congress
Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.
No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.
5% holders (Schedule 13D and 13G)
Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.
| Holder | Percent of class | Shares held | Event date | Form | Source |
|---|---|---|---|---|---|
| PharmAla Biotech Holdings Inc. Common Stock, par value $0.0001 per share | 10.1 | 132,867 | 09/30/2026 Filed 2026-10-26 | SCHEDULE 13G/AAmendment 1 | Open filing 0000912282-26-001403 Dispute this row |
| Orca Capital AG Common Stock, par value $0.0001 per share | 3.3 | 39,945.00 | 08/21/2026 Filed 2026-08-28 | SCHEDULE 13G/AAmendment 1 | Open filing 0001493152-26-040641 Dispute this row |
| Orca Capital AG Common Stock, par value $0.0001 per share | 8.4 | 102,564.00 | 08/21/2026 Filed 2026-08-28 | SCHEDULE 13G | Open filing 0001493152-26-040631 Dispute this row |
| PharmAla Biotech Holdings Inc. Common Stock, par value $0.0001 per share | 17.3 | 132,867 | 08/20/2026 Filed 2026-09-22 | SCHEDULE 13G | Open filing 0000912282-26-001297 Dispute this row |
Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.
What was read
2,632,462 filings read, dated 2004-06-14 to 2026-11-19: Forms 3, 3/A, 4, 4/A, 5, 5/A.
Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.
| Filing year | Filings read |
|---|---|
| 2015 | 49,549 |
| 2016 | 222,642 |
| 2017 | 222,009 |
| 2018 | 223,345 |
| 2019 | 216,482 |
| 2020 | 226,343 |
| 2021 | 249,835 |
| 2022 | 231,682 |
| 2023 | 229,674 |
| 2024 | 234,045 |
| 2025 | 235,520 |
| 2026 | 263,123 |
Filings made before the SEC required XML are listed, not extracted.